|
Tip |
objava |
| 73 |
časopis |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 198 |
časopis |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 201 |
časopis |
Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531. |
| 226 |
časopis |
Walker SE, DeAngelis C, Iazzetta J.
Stability and compatibility of combinations of hydromorphone and a second drug.
Can J Hosp Pharm 1991 ; 44: 289-295. |
| 288 |
časopis |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 300 |
časopis |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 310 |
časopis |
Markowsky SJ, Kohls PR, Ehresman D, Leppik I.
Compatibility and pH variability of four injectable phenytoin sodium products.
Am J Hosp Pharm 1991 ; 48: 510-514. |
| 317 |
časopis |
Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 384 |
časopis |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632. |
| 397 |
časopis |
Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126. |
| 479 |
časopis |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 496 |
časopis |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 619 |
časopis |
Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.
Am J Hosp Pharm 1982 ; 39: 1013-1015. |
| 642 |
časopis |
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA.
Norepinephrine stability in saline solutions.
Hosp Pharm 1988 ; 23: 44,49, 59. |
| 660 |
časopis |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 706 |
časopis |
Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231. |
| 707 |
časopis |
Carmichael RR, Mahoney CD, Jeffrey LP.
Solubility and stability of phenytoin sodium when mixed with intravenous solutions.
Am J Hosp Pharm 1980 ; 37: 95-98. |
| 730 |
časopis |
Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943. |
| 789 |
časopis |
Garner SS, Wiest DB.
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system.
Am J Hosp Pharm 1990 ; 47: 604-606. |
| 921 |
časopis |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 939 |
časopis |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1041 |
časopis |
Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1049 |
časopis |
Klamerus KJ, Ueda CT, Newton DW.
Stability of nitroglycerin in intravenous admixtures.
Am J Hosp Pharm 1984 ; 41: 303-305. |
| 1058 |
časopis |
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691. |
| 1169 |
časopis |
Pfeifle CE, Adler DS, Gannaway WL.
Phenytoin sodium solubility in three intravenous solutions.
Am J Hosp Pharm 1981 ; 38: 358-362. |
| 1193 |
časopis |
Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.
Am J Hosp Pharm 1983 ; 40: 1010-1012. |
| 1625 |
časopis |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1703 |
časopis |
Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103. |
| 1803 |
časopis |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
časopis |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1974 |
časopis |
Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
| 2017 |
časopis |
Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976. |
| 2074 |
časopis |
Tse T, Abdullah R.
Dissolving phenytoin precipitate in central venous access device.
Ann Intern Med 1998 ; 128: 1049. |
| 2090 |
časopis |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2108 |
časopis |
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232. |
| 2109 |
časopis |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2141 |
časopis |
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2231 |
časopis |
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
| 3012 |
časopis |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3152 |
časopis |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3184 |
Traduction Laboratorij |
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005 |
| 3216 |
časopis |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3315 |
poster |
Louvrier M, Dhennain S, Hocahrt S, Zawadski E, Bouffart S, Moquay E.
Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon.
Communication orale Hopipharm 2012 |
| 3316 |
časopis |
Onuki Y, Ikegami-Kawai M, Ishitsuka K, Hayashi Y, Takayama K.
A 5% Glucose Infusion Fluid Provokes Significant Precipitation of Phenytoin Sodium Injection via Interruption of the Cosolvent Effect of Propylene Glycol.
Chem Pharm Bull 2012 ; 60, 1: 86-93. |
| 3372 |
časopis |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
| 3385 |
časopis |
Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182. |
| 3408 |
časopis |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3421 |
časopis |
Leung E, Venkatesan N, Ly S.C, Scheetz M.H.
Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions.
Am J Health-Syst Pharm 2013 ;70:1163-1166. |
| 3525 |
Traduction Laboratorij |
Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012 |
| 3526 |
Traduction Laboratorij |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3531 |
Traduction Laboratorij |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014 |
| 3549 |
Traduction Laboratorij |
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3560 |
Traduction Laboratorij |
Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013 |
| 3588 |
Traduction Laboratorij |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
Sandoz 2011 |
| 3617 |
Traduction Laboratorij |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011 |
| 3620 |
Traduction Laboratorij |
Phenylephrine - Summary of Product Characteristics
Beacon Pharmaceuticals 2012 |
| 3674 |
Traduction Laboratorij |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3767 |
časopis |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3824 |
časopis |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
poster |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
poster |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3932 |
Traduction Laboratorij |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015 |
| 3964 |
časopis |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 |
časopis |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
časopis |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4319 |
časopis |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4428 |
časopis |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
| 4433 |
časopis |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4435 |
časopis |
Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
| 4528 |
časopis |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4603 |
časopis |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4742 |
časopis |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 |
časopis |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
